In mice, chronic subcutaneous administration of metabolically resistant apelin-17 analog, LIT01-196, for 4 weeks post-MI reduced cardiac remodeling by limiting ventricular dilation, LV wall thinning, cardiac fibrosis, and by increasing vascular density and improving systolic performance of the left ventricle as assessed by echocardiography: increased left ventricular ejection fraction and fractional shortening [46]. Here, APLN is linked to myocardial infarction.